Concepedia

Kan Li

KL

36

Publications

3.4K

Citations

23

H-Index

2003

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Texas Health Science Center at Houston

Universidad de La Frontera

University of California, Irvine

Duke University

Kan Li is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and radiation oncology.

ORCID

Top concepts

Publications per year

2003–2024

36

Publications

36

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Nicoletta Colombo, Coraline Dubot, Domenica Lorusso et al. · New England Journal of Medicine · 2021 · 923 citations · Full text

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai et al. · The Lancet · 2023 · 390 citations

, , +7

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Domenica Lorusso, Yang Xiang, Kosei Hasegawa et al. · The Lancet · 2024 · 296 citations

, , +9

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Bradley J. Monk, Nicoletta Colombo, Krishnansu S. Tewari et al. · Journal of Clinical Oncology · 2023 · 191 citations

Interrater Reliability of the Pediatric National Institutes of Health Stroke Scale (PedNIHSS) in a Multicenter Study

Rebecca Ichord, Rachel A Bastian, Lisa Abraham et al. · Stroke · 2011 · 175 citations · Full text

Rows per page

1–5 of 36